Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)

Catalyst Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• Quarterly Finished Goods rose 88.21% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 88.21% YoY) and the FY2025 annual result came in at $16.2 million, up 68.7% from the prior year.
• Finished Goods was $15.3 million for Q1 2026 at Catalyst Pharmaceuticals, down from $16.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $16.2 million in Q4 2025 and bottomed at $8.1 million in Q1 2025.
• A 4-year average of $10.6 million and a median of $9.2 million in 2024 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2025 — Finished Goods slipped 3.29% — and 2026, when it jumped 88.21%.
• Catalyst Pharmaceuticals' Finished Goods stood at $9.2 million in 2023, then rose by 4.55% to $9.6 million in 2024, then surged by 68.7% to $16.2 million in 2025, then declined by 5.43% to $15.3 million in 2026.
• Business Quant data shows CPRX's Finished Goods at $15.3 million in Q1 2026, $16.2 million in Q4 2025, and $11.3 million in Q3 2025.